furazolidone has been researched along with Disease Models, Animal in 16 studies
Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 5.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 5.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| "We have previously demonstrated that in furazolidone-induced congestive heart failure in turkeys the specific Ca(2+)-ATPase activity of myocardial sarcoplasmic reticulum (SR) is 60% increased in compensation for a 50% depression in net Ca(2+)-sequestration activity." | 3.68 | Myocardial calcium cycling defect in furazolidone cardiomyopathy. ( Julian, RJ; Mirsalimi, SM; O'Brien, PJ; Shen, H; Weiler, JE, 1991) |
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 1.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 1.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| "In this model of dilated cardiomyopathy: (1) relaxation is markedly prolonged; (2) the response to beta adrenergic stimulation is diminished; (3) Mg-ATPase activities and myofibrillar protein content are reduced; and (4) sympathetic activity in the heart is markedly increased with depletion of noradrenaline stores." | 1.29 | Pathophysiological and biochemical characterisation of an avian model of dilated cardiomyopathy: comparison to findings in human dilated cardiomyopathy. ( Fuleihan, F; Glass, MG; Gwathmey, JK; Hajjar, RJ; Liao, R; Young, JB, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 7 (43.75) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, M | 2 |
| Wei, J | 2 |
| Shan, H | 2 |
| Wang, H | 1 |
| Zhu, Y | 1 |
| Xue, J | 1 |
| Lin, L | 2 |
| Yan, R | 2 |
| Zhang, R | 1 |
| Zhu, YH | 1 |
| Okafor, CC | 1 |
| Perreault-Micale, C | 1 |
| Hajjar, RJ | 3 |
| Lebeche, D | 1 |
| Skiroman, K | 1 |
| Jabbour, G | 1 |
| Doye, AA | 2 |
| Lee, MX | 1 |
| Laste, N | 1 |
| Gwathmey, JK | 6 |
| Czarnecki, CM | 1 |
| Zhang, SR | 1 |
| Shao, JY | 1 |
| Yu, YW | 1 |
| Van Vleet, JF | 1 |
| Ferrans, VJ | 1 |
| Limas, CJ | 1 |
| Einzig, S | 1 |
| Noren, G | 1 |
| Terekhov, VI | 1 |
| Pavlov, PA | 1 |
| Liao, R | 2 |
| Young, JB | 1 |
| Fuleihan, F | 1 |
| Glass, MG | 1 |
| Nascimben, L | 1 |
| Friedrich, J | 1 |
| Ingwall, JS | 1 |
| Genao, A | 1 |
| Seth, K | 1 |
| Schmidt, U | 1 |
| Carles, M | 1 |
| Kim, CS | 2 |
| Khan, F | 1 |
| DiSalvo, TG | 1 |
| Matsumori, A | 2 |
| Bristow, MR | 1 |
| Goldberg, L | 1 |
| McCoy, Q | 1 |
| Frost, BM | 1 |
| Valiant, ME | 1 |
| Dulaney, EL | 1 |
| O'Brien, PJ | 1 |
| Shen, H | 1 |
| Weiler, JE | 1 |
| Mirsalimi, SM | 1 |
| Julian, RJ | 1 |
| Smith, HJ | 1 |
| Nuttall, A | 1 |
1 review available for furazolidone and Disease Models, Animal
| Article | Year |
|---|---|
Animal models of drug-induced cardiomyopathy.
Topics: Animals; Cardiomyopathies; Daunorubicin; Disease Models, Animal; Doxorubicin; Electrocardiography; E | 1984 |
15 other studies available for furazolidone and Disease Models, Animal
| Article | Year |
|---|---|
Calreticulin-STAT3 signaling pathway modulates mitochondrial function in a rat model of furazolidone-induced dilated cardiomyopathy.
Topics: Animals; Animals, Newborn; Apoptosis; Blotting, Western; Calreticulin; Cardiomyopathy, Dilated; Cell | 2013 |
Suppression of PKCĪµ-mediated mitochondrial connexin 43 phosphorylation at serine 368 is involved in myocardial mitochondrial dysfunction in a rat model of dilated cardiomyopathy.
Topics: Administration, Oral; Animals; Cardiomyopathy, Dilated; Cells, Cultured; Connexin 43; Disease Models | 2015 |
Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Apoptosis; Carbazo | 2003 |
[The protective effects of furazolidone and some commonly used anti-ulcer drugs on several gastric ulcer models in rats].
Topics: Animals; Anti-Ulcer Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Furazo | 1984 |
Furazolidone-induced congestive cardiomyopathy in ducklings: regression of cardiac lesions after cessation of furazolidone ingestion.
Topics: Animals; Cardiomyopathies; Disease Models, Animal; Ducks; Furazolidone; Heart Failure; Male; Myocard | 1983 |
Contrasting effects of spontaneous and induced cardiomyopathy on the nucleoproteins of turkey hearts.
Topics: Animals; Cardiomyopathies; Cell Nucleus; Disease Models, Animal; Furazolidone; Hemodynamics; Myocard | 1982 |
[Therapeutic effectiveness of furazolidone and difuracil (PAP-49) in experimental staphylococcal and Escherichia septicemia].
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Disease Models, Animal; Escherichia coli Infections; Fur | 1995 |
Pathophysiological and biochemical characterisation of an avian model of dilated cardiomyopathy: comparison to findings in human dilated cardiomyopathy.
Topics: Adenosine Triphosphatases; Animals; Calcium; Cardiomyopathy, Dilated; Culture Techniques; Disease Mo | 1993 |
Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance.
Topics: Adenosine Triphosphate; Animals; Cardiomyopathy, Dilated; Creatine; Creatine Kinase; Disease Models, | 1996 |
Dilated cardiomyopathy in turkeys: an animal model for the study of human heart failure.
Topics: Actin Cytoskeleton; Adenylyl Cyclases; Animals; Calcium; Cardiomyopathy, Dilated; Disease Models, An | 1996 |
Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol.
Topics: Adenosine Triphosphate; Adenylyl Cyclases; Adrenergic beta-Antagonists; Animals; Blood Pressure; Bod | 1999 |
Effects of pranidipine, a calcium channel antagonist, in an avian model of heart failure.
Topics: Animals; Anti-Infective Agents, Local; Calcium; Calcium Channel Blockers; Cardiomyopathy, Dilated; D | 1999 |
Antibacterial activity of 3-(1-methyl-5-nitro-2-imidazolylmethylideneamino)-2-oxazolidinone.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Disease Models, Animal; Female; Fura | 1975 |
Myocardial calcium cycling defect in furazolidone cardiomyopathy.
Topics: Animals; Calcium; Calcium Channels; Calcium-Transporting ATPases; Cardiomyopathies; Disease Models, | 1991 |
Experimental models of heart failure.
Topics: Animals; Barbiturates; Blood Pressure; Blood Volume; Cardiomegaly; Cardiomyopathy, Dilated; Cats; Cr | 1985 |